Capsule-type self-gas-generating stomach-capacity-reducing air bag for weight loss

By using temperature-induced gradient gas production composition in self-produced gas-swallowing capsules, the problem of large occupation of acid and alkali reactants and limited gas production capacity in the prior art is solved, and high gas production efficiency and safe and convenient weight loss effect is achieved .

WO2024240128A1PCT designated stage expired Publication Date: 2024-11-28ZHANG QINSHENG +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/094347
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-21
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The existing self-produced gas-swallowing weight loss capsules are large in size and limited in gas production capacity, which leads to excessive volume of capsules, making it difficult to swallow and increase the risk of accidental leakage, and cannot meet the ideal application needs.

Method used

The temperature-induced gradient gas production composition is employed, including 1,1,3,3-pentafluoropropane-ethanol azeotrope, trans-1-chloro-3,3,3-trifluoropropylene, cis-1, Components such as 1,1,4,4-hexafluoro-2-butene are induced by gasification through gastric temperature, and small capsules are designed to reduce capsule volume and material occupancy.

Benefits of technology

It achieves a high gas volume ratio, reduces the capsule volume, improves the convenience and safety of patients' swallowing, meets the needs of weight loss efficacy, and has a gentle and gentle gas production process, and the materials are harmless to the human body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024094347_28112024_PF_FP_ABST
    Figure CN2024094347_28112024_PF_FP_ABST
Patent Text Reader

Abstract

A capsule-type self-gas-generating stomach-capacity-reducing air bag for weight loss, which air bag sequentially comprises, from outside to inside, a gastro-soluble capsule layer, an air bag layer and a gas-generating agent in the air bag. In the present invention, a composition for gradient gas generation under the induction of the intragastric temperature is used as a gas-generating agent, and the self-gas-generating stomach-capacity-reducing air bag for weight loss prepared from the organic inert gas-generating agent composition has stable properties, is harmless to human bodies, can generate more gas at a low volume level, has a high gas-generation volume ratio, and can be conveniently swallowed by a patient without assistance.
Need to check novelty before this filing date? Find Prior Art

Description

A capsule-type self-generating gastric volume and weight reduction airbag Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to a capsule-encapsulated gastric volume and weight reduction airbag that expands using a gas-generating composition induced by a temperature gradient in the stomach. Background Art

[0002] Existing treatments for obesity primarily include diet control, exercise, medication, and surgery. Simply controlling diet and exercising for weight loss requires strong willpower, and most people fail. While surgical weight loss is effective, it requires high medical expertise, causes trauma and a long recovery period, is costly, and causes bodily harm, which Traditional Chinese Medicine (TCM) calls "damaging vital energy," making it difficult for patients to accept.

[0003] In order to overcome the many drawbacks of existing weight loss methods, in recent years many countries have carried out a weight loss method in which water or air balloons are placed in the stomach to occupy the gastric volume and reduce food intake. This method has been proven to be an effective means of weight loss through a large number of practices. This method connects the balloon to a catheter, and the surgeon implants the empty balloon into the stomach, and then injects gas or saline into the balloon to inflate the balloon in the stomach. After completion, the catheter is removed. The intragastric balloon filled with gas or liquid occupies the patient's stomach volume, causing a feeling of fullness, thereby reducing food intake and losing weight. This method is a relatively safe and effective medical weight loss treatment technology. Products that have been approved and clinically used in the United States and other countries include and Spatz3, see CHOI SJ, CHOI HS. Various intragastric balloons under clinical investigation [J]. Clinical Endoscopy, 2018, 51(5): 407–415. However, this method has disadvantages: balloon implantation requires general anesthesia, can easily cause damage to the throat and esophagus, is cumbersome, carries risks, and is painful for the patient.

[0004] ANNALS OF BIOMEDICAL ENGINEERING, 2021, 49: 1391–1401 reported a swallowable, self-gassing weight-loss capsule. The gas-generating mechanism involves placing an aqueous solution of an organic acid (e.g., citric acid) and an alkaline carbonate (e.g., potassium bicarbonate, sodium bicarbonate) separately into different compartments of an intragastric balloon. After the patient swallows the capsule, an external magnetic field is applied to open the magnetic valve of the intragastric balloon, allowing the acid and alkaline reactants to come into contact and react, producing carbon dioxide gas that inflates the balloon. This method avoids the pain of surgery, but it also has some disadvantages:

[0005] 1) Acid-base reactants and water occupy a relatively large volume. According to literature, a capsule measuring 35 mm in length, 12.39 mm in diameter, and with a volume of 4.2 mL (V1) can hold 1.12 grams of the acid-base reactant and 1 mL of water. The resulting gas production is approximately 120 mL (V2), with a gas production volume ratio (V2 / V1) of 120 / 4.2 = 28.57. To achieve the industry-consensus therapeutic volume of 400-600 mL, four capsules would need to be swallowed at once. Numerous studies have documented that the typical number of balloons implanted is one to two. Too small or too many balloons increase the risk of accidental leakage and pyloric obstruction. (The amount of gas produced by a given capsule can be described as the gas production volume ratio: V2 / V1, where V1 is the initial capsule volume and V2 is the volume of the balloon after inflation. A smaller initial capsule volume facilitates spontaneous swallowing, while the goal is to inflate into a larger balloon after entering the stomach.)

[0006] 2) With existing technology, if the capsule's gas production reaches 200 mL, according to the chemical equation for the gas production reaction, each capsule must contain 1.9 grams of reactants and 1.5-2 mL of water. Adding the volume of the balloon material, the total volume reaches approximately 7 mL (13 mm diameter, 45 mm length). Such a large object can easily become lodged or obstructed when passing through the throat or esophagus (especially in narrow areas of the esophagus). If accidental gas production occurs at this time, the consequences are uncontrollable. This can cause patients to fear and find it difficult to swallow voluntarily or fail to swallow.

[0007] From the above, it can be seen that the existing technology is limited by the gas production capacity of acid-base gas generators. Even if the gas production volume ratio of such capsules is close to the theoretical limit, it is still unable to meet the ideal application requirements due to the limitation of capsule volume.

[0008] Therefore, there is a need to improve the self-gas-generating swallowing weight-loss capsule to meet practical needs.

[0009] Summary of the Invention

[0010] In order to address the deficiencies of the prior art, the present invention aims to provide a gastric volume-reducing and weight-reducing capsule that is safe to use and has a high gas production volume ratio, which is convenient for patients to swallow and reduces the amount swallowed, thereby meeting treatment needs.

[0011] To achieve the purpose of the present invention, the present invention provides a composition for inducing gradient gas production by using temperature in the stomach as a gas generating agent, and further makes a capsule-type self-gas-generating gastric volume and weight reduction air bag.

[0012] The technical solution adopted by the present invention is:

[0013] The temperature-induced gradient gas generation composition is composed of the following components, with each component being calculated by mass percentage: component A 1%-20%, component B 5%-30%, component C 55%-95%, component D 0.05%-0.5%, and component E 0.05%-0.5%.

[0014] The preferred composition of the gas generating composition is: component A 1%-10%, component B 5%-20%, component C 70%-90%, component D 0.05%-0.5%, and component E 0.05%-0.5%.

[0015] The component A is selected from: any one or both of 1,1,1,3,3-pentafluoropropane-ethanol azeotrope and trans-1-chloro-3,3,3-trifluoropropene, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluoropropane-ethanol azeotrope is 1%-20%.

[0016] The component B is selected from: any one or both of 1,1,1,3,3-pentafluorobutane-ethanol azeotrope and monofluorotrichloromethane, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluorobutane-ethanol azeotrope is 1%-20%.

[0017] The component C is selected from any one or more of cis-1,1,1,4,4,4-hexafluoro-2-butene, 1,1,1,3,3-pentafluorobutane, and 1-fluoro-1,1-dichloroethane.

[0018] Component D is a flavor alerting agent. Upon accidental rupture of the airbag, it is released into the stomach and, through hiccups, releases the essential oil odor, signaling rupture. Component D is selected from any one or more of eugenol, cinnamaldehyde, eucalyptus essential oil, lavender essential oil, basil essential oil, fennel essential oil, peppermint essential oil, rosemary essential oil, and patchouli essential oil.

[0019] Component E is a color-producing alerting agent. When released into the stomach after an accidental rupture of the airbag, it can cause urine to turn blue or purple, indicating that the airbag has ruptured. The material is selected from any one or more of Prussian blue, methylene blue, and anthocyanin.

[0020] The sum of the proportions of the various components is A%+B%+C%+D%+E%=100%.

[0021] The prepared gas-generating agent is placed in an airbag, excess air is expelled, and the airbag is sealed and folded. The sealed and folded airbag is then placed in a gastric-soluble pressure-bearing capsule for overall encapsulation, thereby producing a gastric-soluble gastric volume and weight reduction capsule with temperature-induced gradient gas generation. The gastric volume and weight reduction capsule comprises, from the outside to the inside, a gastric-soluble pressure-bearing capsule layer, an airbag layer, and a gas-generating agent in the airbag.

[0022] The gastric-soluble pressure-bearing capsule layer is made from modified polyhydroxyalkanoate, hydroxypropyl cellulose, polyvinyl pyrrolidone, and other animal or plant-derived materials. The shell is evenly distributed with multiple ventilation holes, with diameters ranging from 0.2mm to 3mm, for venting gas during overload and pressure relief. This ensures pressure relief without compromising the capsule's pressure-bearing capacity.

[0023] After the capsule enters the stomach, the gastric-soluble pressure-bearing capsule shell can withstand an expansion pressure of 0.2MPa within 20 minutes. Within 20-30 minutes, the capsule disintegrates under the action of gastric juice and releases the air bag.

[0024] Optimal solution: Two disposable pressure overload relief safety valves are installed at both ends of the self-generating air bag body (see Figure 2 2-5). The opening pressure is set to 0.2 MPa. When the pressure in the bag reaches the set value, one of the overload safety valves automatically opens to release air and relieve pressure, which can prevent pressure overload and accidental expansion caused by staying in the esophagus for too long, and prevent damage to the esophagus. The valve is a bursting disc type (non-reclosing overpressure relief device) with a falling-off opening method. The preferred material is a metal film / non-metal composite type. The metal coating not only ensures good barrier properties, but also can be used for CT imaging to understand the position and status of the valve and balloon.

[0025] The capsule-type self-gas-generating gastric volume reduction and weight loss airbag, after the airbag is folded and packaged, the sum of the volumes of all materials (including packaging materials, balloon materials, and gas-generating agents) in the non-gas-generating state is about 2.5mL (V1), and the size of the encapsulated capsule is: 12mm in diameter and 25mm in length; the diameter of the airbag after filling is 73mm-75mm, and the volume is about 200mL (V2). The gas production volume ratio V2 / V1 can reach 80 (the gas production volume ratio is 2.8 times that of the existing technology), and the airbag diameter and the gas-generating agent filling amount can also be appropriately increased to obtain a larger gas production volume ratio and filling volume. The finished product volume of the "weight loss capsule" of the present invention is less than 1 / 2 of the existing acid-base reaction type technical solution, making it easy for patients to swallow it independently. Due to the high gas production volume ratio, only 1-2 capsules need to be swallowed at a time to meet the treatment needs, achieving the current common weight loss efficacy volume.

[0026] By using the simulation device as shown in Figure 4, the capsule of the present invention is used. After swallowing and simulating entering the stomach, the gastric-soluble pressure-bearing encapsulation capsule layer is disintegrated by gastric acid within a preset time of 20 minutes to 30 minutes. At this time, the airbag is freed from the pressure constraint of the pressure-bearing encapsulation capsule layer, and the gas-generating agent sealed in the airbag induces gradient gasification under the temperature environment of 37°C to 40°C in the human stomach (actually measured by the inventor and confirmed in combination with literature data); the airbag completes the expansion process (see Figure B in Figure 2), occupies the volume in the stomach, reduces food intake, and achieves weight loss treatment.

[0027] The principle of the present invention is physical gas production, utilizing intragastric temperature to induce gradient gasification of the gas generating agent composition (see Figure 5 for the temperature-expansion volume curve of the gas generating agent of the present invention). No matching inflation or chemical reaction equipment is required, and the gas generating agent utilization rate is nearly 100%. Less gas generating agent can produce more gas. The main components of the selected composition are biologically inert compounds, and all components are harmless to the human body. The toxicological data of each component are as follows: 1,1,1,3,3-pentafluoropropane toxicological data: No toxicity via the dermal route. When rats and mice were exposed to 203,000 ppm or 101,000 ppm of pentafluoropropane, there was no mortality or significant signs of toxicity (Toxicological Sciences, 1999, 52(2): 289–301). Toxicological data of trans-1-chloro-3,3,3-trifluoropropene: It is non-mutagenic and non-teratogenic. Its toxicity to rodents was negative in the genetic toxicity test. Its toxicity potential to mammals is very low. Male Sprague-Dawley rats and female New Zealand white rabbits were exposed to 2000, 5000 and 10,000 PPM of trans-1-chloro-3,3,3-trifluoropropene, respectively. After 6 hours of exposure, urine was collected within 48 hours and no toxicants were detected (Toxicology and Applied Pharmacology, 2013, 268: 343–351). Toxicological data for chlorofluoromethane: Male and female F-344 rats were exposed to HFIB for 6 hours per day, 5 days per week, at average levels of 0, 29, 62, and 121 ppm for 13 weeks without signs of toxicity (JOURNAL OF THE AMERICAN COLLEGE OF TOXICOLOGY, 1988, 7(5)663-674). Toxicological data for cis-1,1,1,4,4,4-hexafluoro-2-butene: The 4-hour LC50 in rats is 1425 ppm. Fischer-344 rats were exposed to HFIB for 6 hours per day, 5 days per week, at average levels of 3, 10, 30, and 90 ppm for 13 weeks without mortality (TOXICOLOGY AND APPLIED PHARMACOLOGY, 1986, 86:327-340). Toxicological data of 1-fluoro-1,1-dichloroethane: It has very low acute toxicity. No adverse reaction occurs when 2000 mg / kg body weight is applied to the rabbit skin. Oral administration of 5000 mg / kg body weight does not cause death or clinical symptoms of toxicity in rats. The 4-hour LC50 in rats is approximately 62000 ppm. Rats have no significant adverse reactions when repeatedly exposed to concentrations of 2000, 8000 or 20000 ppm for 6 hours / day, 5 days / week, and up to 90 days (Food and Chemical Toxicology, 1995, 33(6): 483-490).Toxicological data of 1,1,1,3,3-pentafluorobutane: The toxicological indicators are lower than those of 1-fluoro-1,1-dichloroethane, making it safer to use in the present invention (JOURNAL OF CELLULAR PLASTICS, 1999, 35: 328-331). Trans-1-chloro-3,3,3-trifluoropropene has been used in the medical field. See the authorized Chinese invention patent CN201180065331, which records that "…suitable materials to be sprayed include, but are not limited to, cosmetic materials such as deodorants, fragrances, hair sprays, cleaning solvents and lubricants, and medical materials such as antiasthmatics. The term medical material is used in this article in its broadest sense to include any and all materials that are effective or at least considered to be effective in treatment, diagnostic methods, analgesia and similar therapies, and thus include, for example, drugs and biologically active substances. Including, for example, the composition of the present invention in an aerosol for delivering drugs to the lungs or mucosa. Examples include metered dose inhalers (MDIs) for treating asthma and other chronic obstructive pulmonary diseases and for delivering drugs to accessible mucosa or intranasal."

[0028] Advantages of the present invention: The composition's main components are organic inert gas generating agents, all of which are stable and harmless to the human body. Gas generation is induced by the temperature inside the stomach, a physical gas generation mechanism. The gas generating agent utilizes nearly 100% of the gas generating agent, produces no byproducts that ineffectively occupy capsule volume, generates a high volumetric efficiency, and the gas generation process is gentle and gentle, with a constant maximum pressure far below that of carbon dioxide. The gas generating agent has a vaporization temperature range of 30°C to 38°C. At 38°C and 1 standard atmosphere, 1 mL of the gas generating agent can be vaporized into approximately 200 mL of gas, a volumetric efficiency far exceeding that of acid-base reaction-based gas generating agents. This allows for the manufacture of smaller weight-loss capsules, making them safer and more convenient to use. A schematic diagram of a sample actually produced and packaged after trial production is shown in Figure 1. Its actual dimensions are 25 mm in length, 12 mm in diameter, and approximately 2.5 mL in volume. Its appearance resembles the rounded cylindrical shape of a typical oral capsule, with a short length and small diameter, making it easier to swallow and more acceptable to patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] FIG1 is the appearance of the gastric-soluble weight-loss capsule of the present invention.

[0030] Figure 2 is a schematic AA cross-sectional view of the gastric-soluble weight-loss capsule of the present invention before and after the airbag is expanded, 2-1 is the gastric-soluble pressure-bearing packaging capsule, 2-2 is the airbag, 2-3 is the gas generating agent, 2-4 is the exhaust hole, and 2-5 is the overload pressure relief safety valve sheet; Figure A is before the airbag is expanded, and Figure B is after the airbag is expanded.

[0031] Figure 3 is a schematic diagram of the comprehensive airbag detection device of the present invention, in which 3-1 is a synchronous constant temperature chamber, 3-2 is a constant temperature water bath, 3-3 is water, 3-4 is a precision pressure gauge, 3-5 is a thermometer, 3-6 is a pressure test gas production bottle, 3-7 is an airbag barrier test port, 3-8 is a gas production test bottle, 3-9 is a measuring cylinder (gas production measurement by drainage method), 3-10 is a material performance test kettle, 3-11 is a membrane material pressure test port, 3-12 is a membrane material barrier test port, 3-13 is an airbag pressure test port, 3-14 is a gastric-soluble pressure-bearing packaging capsule test port, and 3-15 is a valve.

[0032] Figure 4 is a diagram of the swallowing and intragastric test model device: 4-1 constant temperature water bath, 4-2 water, 4-3 esophagus, 4-4 the weight loss capsule of the present invention entering the esophagus and descending, 4-5 simulated stomach, 4-6 simulated gastric contents (water, carboxymethyl cellulose, milk, vegetable puree, and preservative mixture adjusted to pH = 3 with 0.1M hydrochloric acid), and 4-7 is the airbag of the present invention in a filled and expanded state.

[0033] FIG5 is a temperature-expansion volume curve of Example 1 of the present invention.

[0034] FIG6 is a temperature-pressure curve of Example 1 of the present invention. DETAILED DESCRIPTION

[0035] In order to better illustrate the present invention, the present invention is described in detail below with reference to the embodiments and the accompanying drawings.

[0036] Example 1

[0037] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0038] 1% azeotrope of 1,1,1,3,3-pentafluoropropane (97%) and ethanol (3%) and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:1); 20% mixture of monochlorotrifluoromethane and azeotrope of 1,1,1,3,3-pentafluorobutane (95%) and ethanol (5%) (mass ratio of the two is 1:2); 78% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (mass ratio of the three is 4:3:3); 0.5% eugenol; 0.5% methylene blue.

[0039] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production was 0 mL at a temperature below 30°C. At 31°C-34°C, the gas production within 2 minutes was 2.1 mL. At 31°C-34°C, the gas production within 2-10 minutes was 9.7 mL. At 35°C-38°C, the gas production within 2 minutes was 158.9 mL. The maximum gas production at 38°C was 194.0 mL.

[0040] A 200 mL airbag sample was made using a 0.06 mm thick PA / EVOH / PE composite film material as the airbag material. 1.0 g of the aforementioned gas generating agent was filled into the sample and tested at a temperature of 39±1°C under simulated gastric environmental conditions. The airbag volume remained essentially unchanged for 180 days.

[0041] The gas generating agent described in Example 1 was subjected to a temperature-expansion volume test using the apparatus shown in Figure 3. The results are shown in Figure 6. The gas generating agent described in Example 1 was subjected to a temperature-pressure test under the conditions of a 50% excess of gas generating agent and a temperature range of 20°C to 50°C. 1.5 grams of gas generating agent was placed in a 200mL pressure test bottle 3-6, and the maximum pressure measured was 0.0984MPa. The results are shown in Figure 6. This simulates the transient temperature rise in the stomach caused by accidentally swallowing a hot drink or food up to 50°C during the airbag's retention in the stomach. This indicates the minimum expansion pressure that the airbag must withstand at the maximum temperature that the gastric contents may reach. This provides practical reference for selecting or preparing appropriate materials and designing redundant and reliable airbag structural strength.

[0042] Based on the above test results, from the perspective of safety of use: the gas generating agent does not vaporize at room temperature below 30°C. During the swallowing process, the gas generating agent enters the stomach through the esophagus within 2 seconds to 15 seconds. According to the measurement in the model, the gas generating agent gradually heats up in the esophagus but does not reach the vaporization temperature as a whole. If the gas generating agent is accidentally retained in the esophagus after swallowing, even if the gas generating agent exceeds the vaporization temperature as a whole, the air bag will not expand because it is encapsulated in a gastric-soluble pressure-bearing capsule.

[0043] Further explanation regarding safety assurance: The gastric-soluble, pressure-resistant capsules ensure that the self-gassing balloon is not accidentally retained in the stomach for extended periods during storage or when swallowed through the esophagus, and will not vaporize or expand even at body temperature. Upon entering the stomach, the gastric-soluble, pressure-resistant capsules gradually degrade and collapse within 20-30 minutes in the acidic pH 3 environment. The balloon is freed from its pressure-bearing constraints, and the gas-generating agent gradually vaporizes until the balloon is fully inflated. The inflated balloon has a diameter of 73mm-75mm. The maximum size of an object that can pass through the pylorus is no more than 40mm. Therefore, a balloon of this diameter is guaranteed not to pass through the pylorus and enter the intestines.

[0044] The gas generating agent of the above embodiment is used to make "weight-loss capsules", wherein the material for making the airbag must meet the following conditions: a flexible film material with good barrier properties to the gas generating agent of the present invention, non-toxic, and corrosion-resistant, such as PVDC, BOPA, BOPP, BOPET, PVA, EVOH, PE, and their multi-layer composite, multi-layer co-extruded, and coated materials, etc., preferably BOPA coated with PVDC material on the inside with a thickness of 0.06 mm.

[0045] Typically, a weight loss treatment cycle lasts for 180 days. At the end of treatment (or when needed at any time), a needle can be used to puncture the balloon under gastroscopy to extract the gas. After the gas is basically extracted, the deflated balloon can be grabbed through the gastroscope and removed. The balloon can also be made of degradable materials. After the treatment cycle is completed, the balloon degrades and collapses, leaking gas. The deflated balloon remains are discharged from the body through the intestines. The possibility of accidental damage to the balloon cannot be ruled out. In this case, the gas leaks and the balloon deflates, and the remains can be discharged from the body through the intestines. The leaked gas stays in the stomach for a short time and then quickly discharges itself through the digestive tract.

[0046] Example 2

[0047] The gas generating agent is composed of the following components, each component is expressed in mass percentage: 3% of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (the weight ratio of the two is 1:1); 20% of monofluorotrichloromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) azeotrope (the weight ratio of the two is 1:2); 76% of a mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (the weight ratio of the three is 4:3:3); 0.5% lavender essential oil; 0.5% Prussian blue.

[0048] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. At a temperature below 30°C, the gas production was 0 mL. At 31°C-34°C, the gas production within 2 minutes was 6.4 mL. At 31°C-34°C, the gas production within 2-10 minutes was 14.0 mL. At 35°C-38°C, the gas production within 2 minutes was 157.3 mL. The maximum gas production at 38°C was 194.5 mL.

[0049] Example 3

[0050] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0051] 7% of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of 1:1); 5% of monochlorotrifluoromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) azeotrope (weight ratio of 1:1); 87% of a mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of 4:3:3); 0.5% eugenol; 0.5% methylene blue.

[0052] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production was 1.0 mL below 30°C, 14.9 mL within 2 minutes at 31-34°C, 15.6 mL within 2-10 minutes at 31-34°C, 171.4 mL within 2 minutes at 35-38°C, and 195.4 mL at 38°C.

[0053] Example 4

[0054] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0055] 10% azeotrope of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:1); 5% azeotrope of monofluorotrichloromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) (weight ratio of the two is 1:1); 84% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of the three is 4:3:3); 0.5% eugenol; 0.5% methylene blue.

[0056] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production below 30°C was 2.1 mL, the gas production within 2 minutes at 31°C-34°C was 21.2 mL, the gas production within 2-10 minutes at 31°C-34°C was 21.7 mL, the gas production within 2 minutes at 35°C-38°C was 168.0 mL, and the maximum gas production at 38°C was 196.7 mL.

[0057] Example 5

[0058] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0059] 1%, ...

[0060] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production was 0 mL below 30°C, 2.1 mL within 2 minutes at 31°C-34°C, 4.0 mL within 2-10 minutes at 31°C-34°C, 171.6 mL within 2 minutes at 35°C-38°C, and 195.9 mL at 38°C.

[0061] Example 6

[0062] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0063] 1%, 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:1) 1%; 8%, 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) azeotrope (weight ratio of the two is 1:1) 1%; 90%, a mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of the three is 4:3:3) 0.5% eugenol; 0.5% methylene blue.

[0064] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production was 0 mL below 30°C, 2.1 mL within 2 minutes at 31°C-34°C, 3.1 mL within 2-10 minutes at 31°C-34°C, 174.6 mL within 2 minutes at 35°C-38°C, and 197.2 mL at 38°C.

[0065] Example 7

[0066] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0067] 1% azeotrope of 1,1,1,3,3-pentafluoropropane (97%)-ethanol (3%) and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of 1:1); 5% azeotrope of monofluorotrichloromethane and 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%) (weight ratio of 1:1); 93.8% mixture of 1-fluoro-1,1-dichloroethane, 1,1,1,3,3-pentafluorobutane and cis-1,1,1,4,4,4-hexafluoro-2-butene (weight ratio of 4:3:3); 0.1% eugenol; 0.1% methylene blue.

[0068] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production was 0 mL below 30°C, 2.1 mL within 2 minutes at 31°C-34°C, 2.7 mL within 2-10 minutes at 31°C-34°C, 180.3 mL within 2 minutes at 35°C-38°C, and the maximum gas production was 199.1 mL at 38°C.

[0069] Example 8

[0070] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0071] trans-1-chloro-3,3,3-trifluoropropene 15%; monochlorotrifluoromethane 15%; 1-fluoro-1,1-dichloroethane 69.8%; fennel essential oil 0.1%; anthocyanidin 0.1%.

[0072] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production was 4.8 mL below 30°C, 32.0 mL within 2 minutes at 31°C-34°C, 36.4 mL within 2-10 minutes at 31°C-34°C, 172.5 mL within 2 minutes at 35°C-38°C, and 196.7 mL at 38°C.

[0073] Example 9

[0074] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0075] 20% blend of 1,1,1,3,3-pentafluoropropane (95%)-ethanol (5%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:2); 25% azeotrope of 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%); 54.8% cis-1,1,1,4,4,4-hexafluoro-2-butene; 0.1% lavender essential oil; 0.1% Prussian blue.

[0076] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production below 30°C was 7.8 mL, the gas production within 2 minutes at 31°C-34°C was 40.0 mL, the gas production within 2-10 minutes at 31°C-34°C was 62.6 mL, the gas production within 2 minutes at 35°C-38°C was 132.8 mL, and the maximum gas production at 38°C was 178.5 mL.

[0077] Example 10

[0078] The gas generating agent is composed of the following components, each component is expressed in percentage by mass:

[0079] 5% blend of 1,1,1,3,3-pentafluoropropane (95%)-ethanol (5%) azeotrope and trans-1-chloro-3,3,3-trifluoropropene (weight ratio of the two is 1:2); 30% azeotrope of 1,1,1,3,3-pentafluorobutane (95%)-ethanol (5%); 64% cis-1,1,1,4,4,4-hexafluoro-2-butene; 0.1% lavender essential oil; 0.1% Prussian blue.

[0080] 1.0 g of the above-mentioned gas generating agent was placed in the gas production test bottle 3-8 in Figure 3. The gas production below 30°C was 0.5 mL, the gas production within 2 minutes at 31°C-34°C was 10.2 mL, the gas production within 2-10 minutes at 31°C-34°C was 55.4 mL, the gas production within 2 minutes at 35°C-38°C was 152.3 mL, and the maximum gas production at 38°C was 195.1 mL.

[0081] Example 11

[0082] Using the model shown in Figure 4, the "Gastric-Dissolving Volume and Weight Reduction Capsules" prepared by the present invention were injected into the model's stomach via the esophagus with 50 mL of warm water at 25°C. The stomach contents were set to a preset temperature of 38°C. Timing showed that the time it took for the capsule to enter the stomach from the upper esophageal opening with warm water was 2 to 5 seconds. Observation using polarized backlight transillumination revealed that 24 minutes after the capsule entered the stomach, the capsule disintegrated, at which point the internal balloon began to expand with gas production. This expansion ceased at 265 seconds, with the capsule reaching its maximum diameter of 75 mm and a volume of approximately 200 mL.

[0083] The design parameters for the shell disintegration conditions of the gastric-soluble pressure-bearing encapsulation capsule are: at pH = 7, a pressure resistance of 0.2 MPa; at pH = 3, a gastric environment of 35°C-38°C, a disintegration time of 20-30 minutes, and a pressure resistance of 0.1 MPa within 20 minutes. The safety constraint threshold is set as: at a gastric environment of pH = 3, 46°C, a disintegration time ≥ 20 minutes, and a pressure resistance of 0.1 MPa within 20 minutes.

[0084] Example 12

[0085] In a further redundant test, the sample of the gastric volume and weight reduction capsule of the present invention was connected to the test port 3-14 of the airbag comprehensive detection device in Figure 3, and immersed in the simulated gastric content of pH=3. In the temperature range of 38℃-50℃, a point was selected to conduct a pressure time test (the 2-5 overload pressure relief safety valve pieces were placed in a failed state during the test). The gastric-soluble pressure-bearing encapsulated capsule was measured at 46℃ and the pressure inside the capsule was 0.089Mpa. When the constant pressure was maintained for 21 minutes, the capsule collapsed, which was within the preset safety constraint threshold. Simulating hypothetical extreme conditions: at 50℃, the pressure inside the capsule was 0.100Mpa. When the constant pressure was maintained for 12 minutes, the capsule collapsed, which did not reach the preset safety constraint time, that is, the capsule collapse time ≥20 minutes. It is reminded that when swallowing the capsule, hot water exceeding 50℃ should not be used for delivery.

[0086] A pressure test was conducted on the outer layer of the gastric-soluble pressure-bearing capsule: A sample of the gastric-soluble pressure-bearing weight-reducing capsule was connected to test port 3-14 of the airbag integrated testing device in Figure 3 and retained in a simulated mid-esophagus. Compressed air was then injected through port 3-13, pressurizing airbag 2-2 in Figure 2. The pressure test was then conducted at 38°C (the overload pressure relief safety valve in 2-5 was disabled during the test). The pressure was set to 0.400 MPa and maintained constant for 60 minutes. The gastric-soluble pressure-bearing capsule did not burst.

[0087] Example 13

[0088] Swallowing simulation test: The following simulated contents were filled into the encapsulated capsules: an edible starch film occupying a volume of 1.5 mL after folding was taken, and 1 mL of vegetable oil was sealed into the starch film. The trial test capsules were made with the same structure and weight as the capsules of the present invention. The test capsules were swallowed voluntarily by the subjects. A total of 5 people took them with 50 mL of warm water. Each person swallowed 2 capsules at a time, with an interval of 30 seconds between the two swallowings. The time was counted from the time the capsule was placed in the mouth. The shortest time for each capsule was 4 seconds and the longest time was 12 seconds. All capsules were swallowed smoothly.

[0089] It has been determined that under normal stomach temperature of 38°C, the maximum pressure of the gas-generating agent when gas and liquid coexist is 0.059 MPa and is constant. Even if the overload pressure relief safety valve fails, the airbag will not accidentally expand. Therefore, the capsule of the present invention is very safe during use.

[0090] The capsule-type self-generating gastric volume and weight reduction airbag of the present invention is safe, convenient, and easy to use, and is conducive to replacing the currently available products on the market.

Claims

1. A self-gas-generating gastric volume-reducing and weight-reducing capsule, which comprises, from the outside to the inside, a gastric-soluble pressure-bearing capsule layer, an air bag layer and a gas-generating agent in the air bag, characterized in that: The gastric-soluble pressure-bearing capsule layer shell is evenly distributed with air holes; The gas generating agent is composed of the following components, each component is calculated by mass percentage: component A 1%-20%, component B 5%-30%, component C 55%-95%, component D 0.05%-0.5%, component E 0.05%-0.5%; The component A is selected from: any one or two of 1,1,1,3,3-pentafluoropropane-ethanol azeotrope or trans-1-chloro-3,3,3-trifluoropropene, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluoropropane-ethanol azeotrope is 1%-20%; The component B is selected from: any one or two of 1,1,1,3,3-pentafluorobutane-ethanol azeotrope or monofluorotrichloromethane, wherein the mass percentage of ethanol in the 1,1,1,3,3-pentafluorobutane-ethanol azeotrope is 1%-20%; The component C is selected from any one or more of cis-1,1,1,4,4,4-hexafluoro-2-butene, 1,1,1,3,3-pentafluorobutane, and 1-fluoro-1,1-dichloroethane; The component D is a taste alerting agent, selected from any one or more of eugenol, cinnamaldehyde, eucalyptus essential oil, lavender essential oil, basil essential oil, fennel essential oil, peppermint essential oil, rosemary essential oil, and patchouli essential oil; The component E is a color alerting agent selected from any one or more of Prussian blue, methylene blue, and anthocyanin.

2. The self-generating gastric volume and weight reduction capsule according to claim 1, characterized in that: The gas generating agent is composed of the following components, each component is calculated by mass percentage: component A 1%-10%, component B 5%-20%, component C 70%-90%, component D 0.05%-0.5%, component E 0.05%-0.5%.

3. The self-gas-generating gastric volume-reducing and weight-reducing capsule according to claim 1 or 2, characterized in that: A pressure overload relief safety valve is provided at each end of the airbag body.

Citation Information

Patent Citations

  • Self-inflating air bag in digestive tract cavity

    CN101249006A

  • Capsule for stomach capacity reduction and weight reduction

    CN105250060A

  • Systems and methods for determining failure of intragastric devices

    CN109475421A

  • Capsule type self-gas-production stomach volume-reduction and weight-reduction airbag

    CN116602807A

  • Temperature-induced gradient gas self-production composition and application thereof

    CN116603067A